3 Things In Biotech You Should Learn Today: July 3, 2017

Jul. 03, 2017 9:30 AM ETABBV, CARA, MYOV, NBIX, NVCR, TAK6 Comments
Zach Hartman profile picture
Zach Hartman


  • Novocure initiates a big study in pancreatic cancer.
  • Myovant also moves into late-stage studies for its endometriosis drug.
  • Cara Therapeutics stumbles out of the gate in arthritic pain trial.

Welcome to another edition of "3 Things," a daily digest dedicated to helping you unearth important findings from the mountain of news coming out of pharma and biotech. As always, the main goal of this publication is to help get things on your radar that you may have normally missed in your due diligence.

So let's get right to it!

Novocure initiates a big study in pancreatic cancer

Device manufacturer Novocure (NVCR) has made spectacular progress in the treatment of glioblastoma, as it attained approval for its wearable device that sends low-intensity electric fields through the brain in an attempt to target cancerous cells.

From the Novocure website

Not only does this approach work but also it actually appears to work better than standard chemotherapy and with less overall toxicity.

Now, NVCR is setting its sights on even bigger targets. It announced recently that the PANOVA-3 study design is being accelerated due to favorable results from PANOVA-2. The PANOVA suite is assessing the potential benefit of adding tumor-treating fields to one of two standard chemotherapy regimens for "locally advanced, unresectable" pancreatic cancer.

PANOVA-3 is looking to enroll 600 patients, with a primary endpoint of overall survival.

Looking forward: NVCR is getting aggressive in this space, and I like it a lot! PANOVA-2 results were really encouraging compared with historical data, and pancreatic cancer represents a major unmet need in oncology. If this novel treatment modality can make further progress for patients, it will be a big breakthrough. It's a morbid observation, but you can tell just how big an unmet need this is by the primary endpoint of overall survival. Normally, patients with advanced pancreatic cancer do not have a favorable prognosis, which makes the measurement of overall survival relatively simple. Hopefully, NVCR have on hand a great tool to help these patients.

This article was written by

Zach Hartman profile picture
I am a former PhD scientist-turned-writer focused on cancer education. My writings in Seeking Alpha have been devoted to helping people identify promising investment opportunities in cancer research through commentary of recent events. Readers can learn more about other aspects of cancer research by visiting my site Invest Against Cancer.I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.